Intervacc
4.175 SEK 0%Be the first to follow this company
Intervacc is a biotechnology company. The company develops vaccines within animal health care. There is a special focus on the treatment of infections caused by streptococci and staphylococci. The business is run on the basis of various subsidiaries, each with a business focus. Sales take place mainly in the Nordic and Baltic countries. The company's head office is located in Hägersten.
Revenue
8.02M
EBIT %
-1,166.83 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
IVACC
Daily low / high price
4.1 / 4.385
SEK
Market cap
316.2M SEK
Turnover
425.3K SEK
Volume
102K
Financial calendar
General meeting
2024-05-15
Interim report
2024-05-15
Interim report
2024-08-30
Interim report
2024-11-14
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Swedbank Robur Småbolagsfond | 6.8 % | 6.8 % |
Fjärde AP-fonden | 5.0 % | 5.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Kallelse till årsstämma i Intervacc AB (publ)
Intervacc publishes the 2023 Annual Report
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools